新抗原疫苗-话题@MedSci

#新抗原疫苗#

7篇内容 | 977人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2200616, encodeId=510c2200616ed, content=<a href='/topic/show?id=a07f82814ec' target=_blank style='color:#2F92EE;'>#肿瘤免疫治疗#</a> <a href='/topic/show?id=1d4a583e087' target=_blank style='color:#2F92EE;'>#新抗原疫苗#</a>, objectTitle=读书报告 | 新抗原疫苗和免疫检查点抑制剂作用机制的异同, objectType=article, longId=823078, objectId=2cb38230e80f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016299208_4754896.png, objectUrl=/article/show_article.do?id=2cb38230e80f, replyNumber=0, likeNumber=77, createdTime=2024-04-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=2cb38230e80f, moduleTitle=读书报告 | 新抗原疫苗和免疫检查点抑制剂作用机制的异同, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cb38230e80f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2008945, encodeId=e042200894525, content=<a href='/topic/show?id=1d4a583e087' target=_blank style='color:#2F92EE;'>#新抗原疫苗#</a>, objectTitle= Cancer Cell：BioNTech新论文——肿瘤新抗原疫苗+化疗+PD-1，三管齐下治肺癌, objectType=article, longId=737316, objectId=0e77e37316b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e77e37316b6, replyNumber=0, likeNumber=106, createdTime=2023-08-12, rootId=0, userName=daviiliu, userId=5b3f89, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e77e37316b6, moduleTitle= Cancer Cell：BioNTech新论文——肿瘤新抗原疫苗+化疗+PD-1，三管齐下治肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e77e37316b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2008944, encodeId=5de620089449c, content=<a href='/topic/show?id=1d4a583e087' target=_blank style='color:#2F92EE;'>#新抗原疫苗#</a>, objectTitle=新研究预测到2030年，全球癌症新抗原疫苗市场将产生18.261亿美元的收入, objectType=article, longId=186456, objectId=7bd6186456ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bd6186456ae, replyNumber=0, likeNumber=68, createdTime=2020-11-04, rootId=0, userName=daviiliu, userId=5b3f89, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bd6186456ae, moduleTitle=新研究预测到2030年，全球癌症新抗原疫苗市场将产生18.261亿美元的收入, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bd6186456ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2008943, encodeId=0cf5200894373, content=<a href='/topic/show?id=1d4a583e087' target=_blank style='color:#2F92EE;'>#新抗原疫苗#</a>, objectTitle=国际大咖谈：新抗原疫苗能否成为下一个免疫治疗突破口?, objectType=article, longId=181941, objectId=bb641819413d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb641819413d, replyNumber=0, likeNumber=78, createdTime=2020-06-08, rootId=0, userName=daviiliu, userId=5b3f89, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb641819413d, moduleTitle=国际大咖谈：新抗原疫苗能否成为下一个免疫治疗突破口?, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb641819413d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2008942, encodeId=db6b20089425b, content=<a href='/topic/show?id=1d4a583e087' target=_blank style='color:#2F92EE;'>#新抗原疫苗#</a>, objectTitle=Vaccibody肿瘤新抗原疫苗在低突变癌症患者中诱导了强烈的T细胞应答, objectType=article, longId=174386, objectId=c95d1e438698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c95d1e438698, replyNumber=0, likeNumber=79, createdTime=2020-01-27, rootId=0, userName=daviiliu, userId=5b3f89, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c95d1e438698, moduleTitle=Vaccibody肿瘤新抗原疫苗在低突变癌症患者中诱导了强烈的T细胞应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c95d1e438698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2008941, encodeId=876d20089418d, content=<a href='/topic/show?id=1d4a583e087' target=_blank style='color:#2F92EE;'>#新抗原疫苗#</a>, objectTitle=NATURE：新抗原疫苗在Ib期胶质母细胞瘤试验中产生肿瘤内T细胞应答, objectType=article, longId=156415, objectId=bd39156415c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd39156415c5, replyNumber=0, likeNumber=113, createdTime=2019-09-17, rootId=0, userName=daviiliu, userId=5b3f89, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd39156415c5, moduleTitle=NATURE：新抗原疫苗在Ib期胶质母细胞瘤试验中产生肿瘤内T细胞应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd39156415c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2008940, encodeId=31182008940e8, content=<a href='/topic/show?id=1d4a583e087' target=_blank style='color:#2F92EE;'>#新抗原疫苗#</a>, objectTitle=Nature：个性化新抗原疫苗引发强烈抗肿瘤反应,攻克癌症治疗两大障碍！, objectType=article, longId=104787, objectId=935a104e87a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=935a104e87a6, replyNumber=0, likeNumber=90, createdTime=2017-12-08, rootId=0, userName=daviiliu, userId=5b3f89, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=935a104e87a6, moduleTitle=Nature：个性化新抗原疫苗引发强烈抗肿瘤反应,攻克癌症治疗两大障碍！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=935a104e87a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2008939, encodeId=9fc72008939c1, content=<a href='/topic/show?id=1d4a583e087' target=_blank style='color:#2F92EE;'>#新抗原疫苗#</a>, objectTitle=Nature：个性化新抗原疫苗引发强烈抗肿瘤反应,攻克癌症治疗两大障碍！, objectType=article, longId=104784, objectId=aeba104e848a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeba104e848a, replyNumber=0, likeNumber=70, createdTime=2018-02-10, rootId=0, userName=daviiliu, userId=5b3f89, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeba104e848a, moduleTitle=Nature：个性化新抗原疫苗引发强烈抗肿瘤反应,攻克癌症治疗两大障碍！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeba104e848a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

新抗原疫苗

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#肿瘤免疫治疗# #新抗原疫苗#

读书报告 | 新抗原疫苗和免疫检查点抑制剂作用机制的异同

2024-04-26发表于陕西省

daviiliu (审核中...)

前往app查看评论内容

#新抗原疫苗#

Cancer Cell：BioNTech新论文——肿瘤新抗原疫苗+化疗+PD-1，三管齐下治肺癌

2023-08-12

daviiliu (审核中...)

前往app查看评论内容

#新抗原疫苗#

新研究预测到2030年，全球癌症新抗原疫苗市场将产生18.261亿美元的收入

2020-11-04

daviiliu (审核中...)

前往app查看评论内容

#新抗原疫苗#

国际大咖谈：新抗原疫苗能否成为下一个免疫治疗突破口?

2020-06-08

daviiliu (审核中...)

前往app查看评论内容

#新抗原疫苗#

Vaccibody肿瘤新抗原疫苗在低突变癌症患者中诱导了强烈的T细胞应答

2020-01-27

daviiliu (审核中...)

前往app查看评论内容

#新抗原疫苗#

NATURE：新抗原疫苗在Ib期胶质母细胞瘤试验中产生肿瘤内T细胞应答

2019-09-17

daviiliu (审核中...)

前往app查看评论内容

#新抗原疫苗#

Nature：个性化新抗原疫苗引发强烈抗肿瘤反应,攻克癌症治疗两大障碍！

2017-12-08

daviiliu (审核中...)

前往app查看评论内容

#新抗原疫苗#

Nature：个性化新抗原疫苗引发强烈抗肿瘤反应,攻克癌症治疗两大障碍！

2018-02-10

科室
- - 订阅+
  - 更多科室
工具
服务